Colorectal Carcinoma

Canonical Wnt signaling in colon carcinoma cells with APC mutation was inhibited by JW55 treatment.

PMID 22440753 · Waaler et al., 2012 · Open in CIViC

Cell growth of several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell lines with activating BRAF mutations were insensitive, … (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In a study of 468 colorectal adenocarcinoma 61 patients had micro-satellite instability (MSI) and there was a marginally statistically significantly better prognosis for BRAF WT (n=26) patients relati… (full text at CIViC)

PMID 27302369 · Schell et al., 2016 · Open in CIViC

5577 colon carcinoma tumors were evaluated for BRAF, KRAS, and mismatch repair status. From those successfully evaluated, 201 had microsatellite instability (MSI or MSI-H) and BRAF V600E, 72 had MSI a… (full text at CIViC)

PMID 28040692 · Taieb et al., 2017 · Open in CIViC

Case report describing a 63-year-old patient with colorectal adenocarcinoma. He started treatment with XELOX and bevacizumab. After findings of disease progression, they changed to bevacizumab and FOL… (full text at CIViC)

PMID 32162810 · Li et al., 2020 · Open in CIViC

Case report describing a 63-year-old patient with colorectal adenocarcinoma with disease progression after treatment with XELOX-bevacizumab and bevacizumab-FOLFIRI. After the detection of EGFR aberrat… (full text at CIViC)

PMID 32162810 · Li et al., 2020 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. Two cases of… (full text at CIViC)

PMID 31375766 · Solomon et al., 2020 · Open in CIViC

Patient was a 35 year old male who was treated with pseudoadjuvant FOLFOX chemotherapy. Patient relapsed and was found to have an ERBB2 L755S kinase domain mutation along with mutations in APC and BRA… (full text at CIViC)

PMID 27626067 · Aung et al., 2016 · Open in CIViC

FGFR2 over-expression was observed in 75.9 % (n = 107)of the 141 eligible patients and was correlated with perineural invasion (P = 0.005) and inferior tumor regression grading (TRG) (P = 0.009). On u… (full text at CIViC)

PMID 26831663 · Yoon et al., 2016 · Open in CIViC

A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma. Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAA… (full text at CIViC)

PMID 27022066 · Jones et al., 2016 · Open in CIViC

This study finds JAK1 and JAK2 mutation as determinants of primary resistance to PD-1 blockade therapy. Baseline tumors from patients with melanoma and colon cancer who did not respond to PD-1 blockad… (full text at CIViC)

PMID 27903500 · Shin et al., 2017 · Open in CIViC

A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma. Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAA… (full text at CIViC)

PMID 27022066 · Jones et al., 2016 · Open in CIViC

Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab. NGS revealed a frameshift mutation in APC, a missense mutation in KRAS. Variants of uncert… (full text at CIViC)

PMID 27004155 · Loaiza-Bonilla et al., 2016 · Open in CIViC

In a retrospective TCGA cohort of microsatellite-instable colorectal adenocarcinoma (n = 43; KMT2D LOF = 16, WT = 27), KMT2D loss of function was associated with higher TMB (p < 0.001), higher neoanti… (full text at CIViC)

PMID 39578878 · Takemon et al., 2024 · Open in CIViC

In microsatellite-instable (MSI) colorectal carcinoma cell-line assays, KMT2D loss of function (LOF) stratified sensitivity to WRN perturbation. In DepMap viability data, WRN knockout was lethal in MS… (full text at CIViC)

PMID 39578878 · Takemon et al., 2024 · Open in CIViC

FFPE tumor tissue from 1506 colorectal adenocarcinoma patients was analyzed at codons 12, 13, 61 and 146 by PCR. 672 KRAS mutations were found in 670 patients, and from these, two were inframe inserti… (full text at CIViC)

PMID 24642870 · Tong et al., 2014 · Open in CIViC

This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for KRAS exon 2 mutations (l… (full text at CIViC)

PMID 19903786 · He et al., 2009 · Open in CIViC

5577 colon carcinoma tumors were evaluated for BRAF, KRAS, and mismatch repair status. From those successfully evaluated, 201 had microsatellite instability (MSI or MSI-H) and BRAF V600E, 72 had MSI a… (full text at CIViC)

PMID 28040692 · Taieb et al., 2017 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC)

PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-li… (full text at CIViC)

PMID 26546295 · Russo et al., 2016 · Open in CIViC

A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, an… (full text at CIViC)

PMID 26546295 · Russo et al., 2016 · Open in CIViC

To assess the effects of MSH3 status on chemosensitivity, MSH3-deficient and MSH3-proficient HCT116 cells were treated with oxaliplatin, SN-38 (irinotecan metabolite), and 5-FU. Parental MSH3-deficien… (full text at CIViC)

PMID 23724141 · Park et al., 2013 · Open in CIViC

47 patients with locally advanced rectal cancer were treated with dostarlimab. 41 completed treatment and achieved a clinical complete response. No patients experienced local or distant disease recurr… (full text at CIViC)

Open in CIViC

Patients with the wild type (C/C) MTHFR gene are 2.91 times (95% CI: [1.23, 6.89]) more likely to have a positive response to neoadjuvant CRT and 3.25 times more likely not to experience relapse (95%… (full text at CIViC)

PMID 26693073 · Nikas et al., 2015 · Open in CIViC

In a retrospective cohort analysis of colon adenocarcinoma treated with PD-1/PD-L1 immune checkpoint inhibitors from the MSKCC ICIs-treated COAD dataset (n = 76; NCOA3-mutant n = 7, NCOA3-wild-type n … (full text at CIViC)

PMID 40215778 · Liu et al., 2025 · Open in CIViC

Finally, treatment of CRC cells with anti-Notch2/3 antibody increased Numb protein while significantly reducing formation of spheroids in both MICOL-14tum cells and primary tumor cultures. This novel … (full text at CIViC)

PMID 24525742 · Pastò et al., 2014 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA exon 10 and 21 mu… (full text at CIViC)

PMID 19903786 · He et al., 2009 · Open in CIViC

This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA mutations in exon… (full text at CIViC)

PMID 19903786 · He et al., 2009 · Open in CIViC

Patients with metastatic colorectal cancer with STRN-ALK fusion, sporadic microsatellite instability high (MSI-H) and KRAS R164Q received ALK inhibitor ceritinib. After pts received ceritinib perinumb… (full text at CIViC)

PMID 26933125 · Yakirevich et al., 2016 · Open in CIViC

This study evaluated genomic biomarkers associated with treatment response and clinical outcomes in patients with locally advanced rectal adenocarcinoma (LARC) treated with neoadjuvant chemoradiation … (full text at CIViC)

PMID 37260182 · Lee et al., 2023 · Open in CIViC

In a single-center observational study of 102 patients with microsatellite stable (MSS) metastatic colon cancer receiving standard treatments, high tumor mutational burden (TMB ≥10 mutations/Mb) was a… (full text at CIViC)

PMID 39639373 · Di Mauro et al., 2024 · Open in CIViC

26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potenti… (full text at CIViC)

PMID 19737969 · Lin et al., 2009 · Open in CIViC

A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Bre… (full text at CIViC)

PMID 24296758 · Aisner et al., 2014 · Open in CIViC